Navigation Links
The Lancet Publishes Vasogen's ACCLAIM Results
Date:1/18/2008

MISSISSAUGA, ON, Jan. 18 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that The Lancet, a world-leading medical journal, will publish an article entitled 'Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial' in its January 19th issue (Lancet 2008; 371: 228-36). The article describes the results from Vasogen's 2,400-patient ACCLAIM trial of its Celacade(TM) system in patients with chronic heart failure. Celacade is designed to target the destructive chronic inflammation underlying the development and progression of chronic heart failure.

The interpretation of the findings in The Lancet is that: "Non-specific immunomodulation (Celacade) may have a role as a potential treatment for a large segment of the heart failure population, which includes patients without a history of myocardial infarction (irrespective of their functional NYHA class) and patients within NYHA class II."

While the ACCLAIM study did not meet its primary endpoint for the intent-to treat-population, this primary endpoint was met for two large pre-specified subgroups of patients. In the trial, Celacade was shown to significantly reduce the risk of death or cardiovascular hospitalization by 39% in the subgroup of 689 patients with NYHA Class II heart failure, and by 26% in the subgroup of 919 patients with no prior history of heart attack. Importantly, the large risk reduction observed in these subgroups was achieved on top of the benefits derived from current standard-of-care medications and device therapy for heart failure.

"We are extremely pleased with the publication of the ACCLAIM results in The Lancet," commented Chris Waddick, President a
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
2. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
3. Consortium publishes Phase II map of human genetic variation
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. CNS Response Announces Fiscal Third Quarter 2007 Results
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 30, 2014 Two separate delegations ... hosted by Charm Sciences at its Andover, Massachusetts ... in the US, the participants discussed international systems ... management, and process verification, and received hands-on technical ... was the first visit to the United States ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... Fla. , Oct. 31, 2014  Tavistock ... owned by Tavistock Group, celebrated the groundbreaking of the ... Medical City. The 92,000-square-foot, three-story ... Central Florida designed specifically for ... in the heart of the 650-acre Lake Nona ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Charm Sciences Hosts Executives from Latin America for Dairy Safety Executive Seminar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
... Dan Ross to Lead Business Development Team , , ... that provides pricing and reimbursement services to pharmaceutical and biotechnology companies, ... open its new San Diego office. , , ... both investment banking and strategic consulting capacities. His primary role ...
... INCLINE VILLAGE, Nev., Sept. 8 PDL BioPharma, Inc. ... for the third quarter ended September 30, 2009 of approximately ... quarter of 2008. Royalty revenues are based on second quarter ... Synagis(R), which is marketed by MedImmune. When compared with 2008, ...
... Sept. 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE Amex: ... announced,that the first lot of PANFLU.1, its H1N1 vaccine, has ... Control of Pharmaceutical and,Biological Products and obtained the Certificate for ... ready for delivery. , The released ...
Cached Biology Technology:PriceSpective Continues Global Expansion With New San Diego Office 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine 2
(Date:10/29/2014)... a consequence of chemotherapy will benefit from a major ... that prevents hair loss. , The research is being ... cooling manufacturing company, Paxman Coolers, of Fenay Bridge, Huddersfield, ... of Huddersfield. , The research will be led by ... the pharmacology of cancer treatment, which he will use ...
(Date:10/29/2014)... Beaverton, OR) New research presented at the ... in Houston, TX showed for the first time ... in women using a readily available nutritional supplement, ... by Dr. Judith A. Smith, Pharm.D., associate professor ... Sciences at The University of Texas Health Science ...
(Date:10/29/2014)... factors, both genetic and environmental, have been blamed ... schizophrenia. Some, such as a family history of ... with Toxoplasma gondii , a parasite transmitted ... still viewed with skepticism. , A new study ... epidemiology at the University of Pennsylvania,s School of ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... the brain than previously thought, a new study shows. ... first detected by part of the brain called primary visual ... head where visual information first enters the cortex of the ... in animals but has not been tested on human beings ...
... (September 5, 2007) King Abdullah University of Science ... Cairo (AUC) signed a Memorandum of Understanding on August ... development that will positively impact the Kingdom of Saudi ... president of KAUST, and Dr. David D. Arnold, president of ...
... of Engineering may have discovered the path toward ... bacteria that have developed resistance to common antibiotics. ... of events occurring in bacteria that opens to ... Currently, three classes of bactericidal antibiotics are used ...
Cached Biology News:Color contrast is 'seen' by the brain early doors 2KAUST and American University in Cairo to collaborate on research and academic development 2Boston University biomedical engineers find chink in bacteria's armor 2Boston University biomedical engineers find chink in bacteria's armor 3
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Arginine vasopressin receptor (AVP-V2), rat. The peptide used for immunization has no significant similarity with AVP V1a or V1b receptors....
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Biology Products: